These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11937175)

  • 21. [Lowering blood pressure with sartans. Are there differences?].
    MMW Fortschr Med; 2002 Nov; 144(47):63. PubMed ID: 12532530
    [No Abstract]   [Full Text] [Related]  

  • 22. [Organ protection by angiotensin II receptor blockers].
    Kumagai H; Onami T; Takimoto C; Iigaya K; Saruta T
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():569-73. PubMed ID: 15171437
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibition of the renin-angiotensin system does not reduce platelet activity at rest or during stress in hypertension.
    Schwieler JH; Kahan T; Wallén NH; Nussberger J; Hjemdahl P
    J Hypertens; 2013 Aug; 31(8):1676-82. PubMed ID: 23625113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of losartan and captopril in ELITE II.
    Hall A
    Lancet; 2000 Sep; 356(9232):851; author reply 852-3. PubMed ID: 11022946
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of eplerenone versus losartan in patients with low-renin hypertension.
    Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
    Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis.
    Tylicki L; Renke M; Rutkowski P; Rutkowski B; Lysiak-Szydłowska W
    Med Sci Monit; 2005 Apr; 11(4):PI31-7. PubMed ID: 15795705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of angiotensin II-antagonists].
    Internist (Berl); 1998 Sep; 39(9 Suppl Zum Stelle):1-4. PubMed ID: 9772714
    [No Abstract]   [Full Text] [Related]  

  • 28. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
    Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
    Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy for hypertension associated with kidney disease].
    Suzuki H
    Nihon Naika Gakkai Zasshi; 2003 Feb; 92(2):264-9. PubMed ID: 12652731
    [No Abstract]   [Full Text] [Related]  

  • 30. [Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
    Winkler G; Jermendy G; Matos L
    Orv Hetil; 2003 Sep; 144(38):1861-7. PubMed ID: 14596024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R; Siva S; Dunn SR; Sharma K
    Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Successful use of angiotensin II receptor antagonist (losartan) in a patient with scleroderma renal crisis].
    Hasegawa S; Iesato K; Tsukahara T; Yamamoto S; Kondou Y; Ogawa M; Ueda S
    Nihon Jinzo Gakkai Shi; 2000 Feb; 42(2):60-5. PubMed ID: 10771577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. All that glitters is not gold.
    Velazquez EJ; Califf RM
    Lancet; 2000 May; 355(9215):1568-9. PubMed ID: 10821355
    [No Abstract]   [Full Text] [Related]  

  • 35. [Changed guidelines of the German High Blood Pressure League. AT(1) blocker in the first league now].
    MMW Fortschr Med; 2002 Oct; 144(44):55. PubMed ID: 12494603
    [No Abstract]   [Full Text] [Related]  

  • 36. [Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
    Baumgart P
    MMW Fortschr Med; 2006 Mar; 148(11):57, 59-60. PubMed ID: 16612965
    [No Abstract]   [Full Text] [Related]  

  • 37. Hypertensive pulmonary oedema is due to diastolic dysfunction.
    Little WC
    Eur Heart J; 2001 Nov; 22(21):1961-4. PubMed ID: 11603900
    [No Abstract]   [Full Text] [Related]  

  • 38. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
    Agarwal R
    Am J Physiol Renal Physiol; 2003 Apr; 284(4):F863-9. PubMed ID: 12505865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
    Hesse U; Godman B; Petzold M; Martin A; Malmström RE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):677-85. PubMed ID: 24105097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
    Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
    Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.